Particularly, the SCN9A gene represents an ideal target for treating chronic pain in the context of SMA as well other diseases as disruption of this gene alone leads to lack of pain but appears not to cause other health issues except anosmia63,64. This evidence concerns the gene SCN9A and proximal spinal muscular atrophy.